Colorectal Cancer
Research activity in colorectal cancer includes treatment strategies for advanced and refractory disease, with interest in immunotherapy, targeted therapy, and combinations with established chemotherapy backbones. The sponsor also supports work in molecularly defined disease, including DNA homologous-repair deficiency and metastatic disease with limited liver involvement.
- Advanced colorectal cancer
- Homologous-repair-deficient disease
- Liver-limited metastatic disease
- Anti-EGFR and anti-VEGF-based treatment
These studies reflect a strong focus on systemic control of metastatic colorectal cancer and on improving outcomes in patients with poor-prognosis disease patterns.
Locally Advanced Rectal Cancer
The sponsor is active in locally advanced rectal cancer, with research centered on total neoadjuvant therapy and immune checkpoint blockade alongside chemoradiotherapy. The therapeutic emphasis is on achieving pathological complete response and deeper local disease control.
- Total neoadjuvant therapy
- Durvalumab-based combinations
- Radiotherapy integration
- Pathological complete response
Interest in this area highlights a focus on treatment intensification for rectal cancer and on optimizing multimodal care in the curative-intent setting.
Anal Canal Squamous Cell Carcinoma
Clinical research also includes squamous cell carcinoma of the anal canal, with attention to immunotherapy combined with chemoradiotherapy for localized disease. The key therapeutic aim is achieving clinical complete response and durable local remission.
- Atezolizumab-based treatment
- Tiragolumab combinations
- Chemoradiotherapy
- Clinical complete response
This area reflects involvement in anal cancer management through combined-modality approaches that integrate systemic and local treatment.
